Clinical Trials Logo
  1. Home
  2. Pancreatic Cancer Metastatic
  3. NCT01652976

Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma — FOLFOX-D  

Pancreatic Cancer Metastatic Clinical Trial

Official title:
Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib (FOLFOX-D) in First-line Metastatic Pancreatic Adenocarcinoma

Clinical Trial Summary

The purpose of this research study is to determine if the study drug, dasatinib, given in combination with 5-Fluorouracil, leucovorin and oxaliplatin (FOLFOX) will work against metastatic pancreatic cancer. Dasatinib is a Food and Drug Administration (FDA) approved drug for treating chronic myelogenous leukemia and acute lymphoblastic leukemia, however it is not currently approved for use in the treatment of pancreatic cancer.

Clinical Trial Description

Systemic control of pancreatic cancer remains a clinical unmet need. The recent superiority of 5-FU based combination therapies over the historical standard gemcitabine represents an opportunity to develop novel combinations of synergistic and effective cytotoxic and biologic targeted therapies. Src excess activity has been demonstrated in pancreatic cancer and is implicated in the invasive and metastatic phenotype clearly represented by this disease. Inhibition of Src activity is associated with numerous biologic modifications capable of positively modifying this phenotype and appears to have synergy with restoring inherent chemosensitivity. The addition of dasatinib to FOLFOX (FOLFOX-D) represents a novel therapeutic regimen in pancreatic cancer with safety and pharmacokinetic data already having been established in colorectal cancer. This protocol will test the safety and activity of this combination in pancreatic cancer where current clinical outcomes remain far from optimal. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01652976
Study type Interventional
Source University of Florida
Contact
Status Completed
Phase Phase 2
Start date July 2012
Completion date July 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06155136 - RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
Not yet recruiting NCT05047991 - Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma Phase 2
Active, not recruiting NCT04469556 - Pancreatic Adenocarcinoma Signature Stratification for Treatment Phase 2
Completed NCT03504423 - Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas Phase 3
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Withdrawn NCT04799431 - Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer Phase 1
Recruiting NCT04674956 - A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer Phase 3
Completed NCT03412799 - Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Phase 1
Withdrawn NCT04852367 - PanDox: Targeted Doxorubicin in Pancreatic Tumours Phase 1
Recruiting NCT04467593 - Safety Study of Whole Body Hyperthermia for Advanced Cancer N/A
Recruiting NCT02959151 - A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy Phase 1/Phase 2
Completed NCT04721301 - Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial Phase 1
Recruiting NCT04667403 - Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer N/A
Recruiting NCT06168812 - A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer Phase 2
Not yet recruiting NCT06076837 - The Seven Trial: Exploiting the Unfolded Protein Response Phase 1
Active, not recruiting NCT03984214 - Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer Phase 3
Recruiting NCT05254171 - Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer Phase 2/Phase 3
Recruiting NCT04116073 - INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer Phase 2
Recruiting NCT04338763 - RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer Phase 1
Recruiting NCT06030622 - Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer Phase 1/Phase 2